Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Berlin - Delayed Quote • EUR Fresenius SE & Co KGaA (FRE.BE) Follow Add holdings 39.95 +0.14 +(0.35%) At close: April 25 at 9:52:04 PM GMT+2 All News Press Releases SEC Filings Investors more bullish on Fresenius SE KGaA (ETR:FRE) this week as stock ascends 5.8%, despite earnings trending downwards over past year If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost... Is Concentra Group Holdings Parent, Inc. (CON) Outperforming Other Medical Stocks This Year? Here is how Concentra Group (CON) and Fresenius (FMS) have performed compared to their sector so far this year. Here's Why Fresenius (FMS) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock? Delcath Systems (DCTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog. Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news. PCRX Stock Soars on Exparel Patent Settlement With Generic Players Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030. Update: Pacira Biosciences Settles Patent Litigations Over Local Analgesic; Shares Rise Pre-bell (Updates with stock price movement in the first paragraph and headline.) Pacira Biosciences (PCRX Pacira Biosciences Settles Patent Litigations Over Local Analgesic Pacira Biosciences (PCRX) said Monday it settled the litigations with Fresenius Kabi USA, Jiangsu He Why Is Nevro (NVRO) Up 0.9% Since Last Earnings Report? Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Why Fresenius (FMS) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. Fresenius SE KGaA Full Year 2024 Earnings: EPS Misses Expectations Fresenius SE KGaA ( ETR:FRE ) Full Year 2024 Results Key Financial Results Revenue: €21.8b (up 3.6% from FY 2023). Net... Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Fresenius SE & Co. KGaA's (ETR:FRE) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? Fresenius SE KGaA's (ETR:FRE) stock is up by a considerable 16% over the past three months. However, we decided to pay... Here's Why Fresenius (FMS) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Is Alignment Healthcare (ALHC) Stock Outpacing Its Medical Peers This Year? Here is how Alignment Healthcare (ALHC) and Fresenius (FMS) have performed compared to their sector so far this year. Fresenius Sells Fresenius Medical Care Stake For $1.15 Billion The healthcare company said it had sold 3.6% of Fresenius Medical Care’s share capital and that it would use the proceeds to help strengthen its balance sheet and reduce leverage. Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)? Fresenius SE & Co. KGaA ( ETR:FRE ) saw a decent share price growth of 19% on the XTRA over the last few months. The... Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and ... Fresenius SE & Co KGaA (FSNUF) reports robust financial performance with significant revenue and EBIT growth, while navigating macroeconomic challenges and strategic shifts. Performance Overview Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) Return FRE.BE DAX P (^GDAXI) YTD +18.97% +11.72% 1-Year +47.31% +24.14% 3-Year +25.32% +59.74%